Why so hypoxic?

RefeRences 1 Mahler SA, Register TC, Riley RF, et al. Monocyte chemoattractant protein1 as a predictor of coronary atherosclerosis in patients receiving coronary angiography. Crit Pathw Cardiol 2018;17:105–10. 2 Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004;44:1812–8. 3 Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein1 in human atheromatous plaques. J Clin Invest 1991;88:1121–7. 4 Hoogeveen RC, Morrison A, Boerwinkle E, et al. Plasma MCP1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis risk in Communities study. Atherosclerosis 2005;183:301–7. 5 Schecter AD, Rollins BJ, Zhang YJ, et al. Tissue factor is induced by monocyte chemoattractant protein1 in human aortic smooth muscle and THP1 cells. J Biol Chem 1997;272:28568–73. 6 Gosling J, Slaymaker S, Gu L, et al. Mcp1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773–8. 7 GonzalezQuesada C, Frangogiannis NG. Monocyte chemoattractant protein1/ccl2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 2009;11:131–8. 8 Mitchell AM, Garvey JL, Kline JA. Multimarker panel to rule out acute coronary syndromes in lowrisk patients. Acad Emerg Med 2006;13:803–6. 9 de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein1 and longterm clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690–5. 10 de Lemos JA, Morrow DA, Blazing MA, et al. Serial measurement of monocyte chemoattractant protein1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007;50:2117–24. 11 Greenslade JH, Carlton EW, Van Hise C, et al. Diagnostic accuracy of a new highsensitivity troponin I assay and five accelerated diagnostic pathways for ruling out acute myocardial infarction and acute coronary syndrome. Ann Emerg Med 2018;71:439–51. 12 Mahler SA, Riley RF, Hiestand BC, et al. The heart pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. Circ Cardiovasc Qual Outcomes 2015;8:195–203. 13 Body R, Morris N, Reynard C, et al. Comparison of four decision AIDS for the early diagnosis of acute coronary syndromes in the emergency department. Emerg Med J 2020;37:8–13. 14 Mahler SA, Miller CD, Hollander JE, et al. Identifying patients for early discharge: performance of decision rules among patients with acute chest pain. Int J Cardiol 2013;168:795–802. 15 Than M, Flaws D, Sanders S, et al. Development and validation of the emergency department assessment of chest pain score and 2 H accelerated diagnostic protocol. Emerg Med Australas 2014;26:34–44. 16 Stopyra J, Snavely AC, Hiestand B, et al. Comparison of accelerated diagnostic pathways for acute chest pain risk stratification. Heart 2020;106:977–84. 17 Mahler SA, Lenoir KM, Wells BJ, et al. Safely identifying emergency department patients with acute chest pain for early discharge. Circulation 2018;138:2456–68. 18 Stopyra JP, Riley RF, Hiestand BC, et al. The heart pathway randomized controlled trial oneyear outcomes. Acad Emerg Med 2019;26:41–50. 19 Body R, Carlton E, Sperrin M, et al. Troponinonly Manchester acute coronary syndromes (TMACS) decision aid: single biomarker rederivation and external validation in three cohorts. Emerg Med J 2017;34:349–56. 20 The EQUATOR Network. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Available: http://www.equator-network.org/reporting-guidelines/strobe/ [Accessed 31 May 2019]. 21 Allen BR, Christenson RH, Cohen SA, et al. Diagnostic performance of highsensitivity cardiac troponin T strategies and clinical variables in a multisite US cohort. Circulation 2021;143:1659–72. 22 Christenson E, Christenson RH. Characteristics of cardiac troponin measurements. Coron Artery Dis 2013;24:698–704. 23 Christenson RH, Jacobs E, UettwillerGeiger D, et al. Comparison of 13 commercially available cardiac troponin assays in a multicenter North American study. J Appl Lab Med 2017;1:544–61. 24 IFCC troponin tables ug_L_Update_December 2012. pdf. Available: http://www.ifcc. org/media/218183/IFCC%20Troponin%20Tables%20ug_L_Update_December% 202012.pdf [Accessed 30 Jul 2021]. 25 Jossi S, Gordon SL, Legge MA, et al. All troponins are not created equal. Intern Med J 2006;36:325–7. 26 Human CCL2/MCP1 Quantikine ELISA kit. www. rndsystems. com. Available: https:// www.rndsystems.com/products/human-ccl2-mcp-1-quantikine-elisa-kit_dcp00 [Accessed 18 Jul 2021]. 27 Fitzgerald RL, Hollander JE, Peacock WF, et al. Analytical performance evaluation of the Elecsys® troponin T gen 5 STAT assay. Clin Chim Acta 2019;495:522–8. 28 Hollander JE, Blomkalns AL, Brogan GX, et al. Standardized reporting guidelines for studies evaluating risk stratification of emergency department patients with potential acute coronary syndromes. Ann Emerg Med 2004;44:589–98. 29 Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018;72:2231–64. 30 Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763–70. 31 Mitchell AM, Garvey JL, Chandra A, et al. Prospective multicenter study of quantitative pretest probability assessment to exclude acute coronary syndrome for patients evaluated in emergency department chest pain units. Ann Emerg Med 2006;47:447. e1.